Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. Our clinical-stage product candidates include: Phase 3 HEPLISAV-B ™ Adult Hepatitis B Vaccine Phase 1/2 Cancer Immunotherapy Phase 2 Asthma Therapy - Partnered with AstraZeneca In Europe, Dynavax manufactures Hepatitis B surface antigen for HEPLISAV-B.

Type
Public
HQ
Berkeley, US
Employees
234 (est)
Dynavax Technologies is headquartered in Berkeley, US

Dynavax Technologies Locations

Berkeley, US

Dynavax Technologies Metrics

Dynavax Technologies Summary

Market capitalization

$375 M

Closing share price

$9.6
Dynavax Technologies's latest market capitalization is $375 M.

Dynavax Technologies Market Value History

Dynavax Technologies News

Dynavax Technologies Company Life

You may also be interested in